Donepezil Hydrochloride
Product Images NDC 42658-130

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 42658-130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hisun Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

8088a70f-figure-01 (8088a70f Figure 01)

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure1.jpg (8088a70f Figure 02)

This text mentions the change in ADAS-cog score from baseline after 12 and 18 weeks of drug treatment with Donepezil Hydrochloride (at 5mg/day and 10mg/day) and Placebo. It suggests that the data includes information on clinical improvement and decline over the treatment period.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure2.jpg (8088a70f Figure 03)

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure3.jpg (8088a70f Figure 04)

This text appears to be a record of the percentage of patients with varying levels of improvement after treatment with Donepezil Hydrochloride or Placebo according to the CIBIC-plus Rating scale. The percentages of patients falling into different categories of improvement are shown for Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and Placebo.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure4.jpg (8088a70f Figure 05)

This text is a table displaying the AADAS-cog change from baseline for different treatments over various weeks of drug treatment. It compares the mean change in AADAS-cog score between Donepezil Hydrochloride at 10 mg/day, Donepezil Hydrochloride at 5 mg/day, and Placebo. The table indicates the timeline in weeks and illustrates clinical improvement or changes in baseline.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure5.jpg (8088a70f Figure 06)

This information is about the cumulative percentage of patients experiencing a change in ADAS-cog scores under different treatment groups. It includes data for Donepezil Hydrochloride at two different dosages as well as a placebo group. The graph represents the change from baseline in ADAS-cog scores for each treatment group over a certain period of time.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure6.jpg (8088a70f Figure 07)

This data appears to be related to a study or evaluation of patients receiving different treatments (Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and Placebo) with their corresponding assessments of improvement or worsening based on the CIBIC-plus Rating scale. The text includes information on the number of patients in each group and their perceived level of change in improvement.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure7.jpg (8088a70f Figure 08)

This text provides data on the mean change in clinical improvement measured in pounds sterling (mean £) for patients taking Donepezil Hydrochloride 10 mg/day compared to placebo over a period of 3 months of drug treatment. It seems to be related to a study or clinical trial evaluating the effects of Donepezil Hydrochloride on clinical improvement.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure8.jpg (8088a70f Figure 09)

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure9.jpg (8088a70f Figure 10)

This text describes a comparison between the clinical improvement of patients receiving Donepezil Hydrochloride 10 mg/day treatment and those receiving a placebo over a period of 3 to 6 months. The study evaluates the decline in clinical performance between the two groups.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure10.jpg (8088a70f Figure 11)

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure11.jpg (8088a70f Figure 12)

This text provides information about two dosages of Donepezil Hydrochloride: 23 mg/day and 10 mg/day. The document also mentions clinical improvement and SIB change from baseline over the course of drug treatment at different time points.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure12.jpg (8088a70f Figure 13)

Cumulative Percentage of Patients for Donepezil Hydrochloride at 23 mg/day is 100%, while for Donepezil Hydrochloride at 10 mg/day is 4%. The SIB (Severe Impairment Battery) Change from Baseline is -40, indicating a decrease in cognitive function.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure13.jpg (8088a70f Figure 14)

This text appears to be a table showing the assessment of patients based on the change in their conditions after taking different dosages of Donepezil Hydrochloride. The table includes categories like "Markedly," "Moderately," "Minimally," and "No" improvement in comparison to the initial condition. The evaluation also includes a comparison of different dosages (23 mg/day and 10 mg/day) of Donepezil Hydrochloride. CIBIC-plus Rating seems to be the assessment scale used in this evaluation.*

FDA Label Image

C:\users\admin\desktop\donepezil Spl\label-90ct.jpg (8088a70f Figure 15)

Each film-coated tablet of Donepezil Hydrochloride Tablets, USP contains 23 mg of donepezil hydrochloride. The tablets should be stored at a temperature between 20°C to 25°C (68°F to 77°F). Dispense in tight containers as per USP guidelines. The usual dosage information can be found in the accompanying prescribing information. The tablets are labeled with NDC 42658-130-04 and come in a package of 90 tablets with a strength of 23 mg. This product is for prescription-only use. Distributed by Hisun Pharmaceuticals USA, Inc. and manufactured by QS Pharma, LLC, the tablets are 30 mm x 15 mm in size and are unvarnished. Please refer to the packaging for further details.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.